Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and ILI With Melphalan and Dactinomycin for Extremity Sarcoma
NCT04332874Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2020
- Primary completion
- Apr 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in sarcoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2020; status: recruiting.
02
Drugs
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT04332874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04332874.